Ace Therapeutics' organ toxicology research services can provide valuable data and references for the development of new antipsychotic drugs to ensure the development of safer and more effective treatment options.

The Importance of Organ Toxicity Assessment of Antipsychotic Drugs

The development of antipsychotic medications has changed the practice of psychiatry. However, these drugs can cause severe toxicity after overdose, which is common in patients with psychiatric disorders. They have also been associated with many adverse effects, primarily involving the cardiovascular, endocrine, and neurological systems. Toxicology studies of antipsychotic drugs can be used to assess the negative effects and side effects that these drugs may cause in the treatment of psychiatric disorders. In addition, toxicology studies of these drugs can help physicians better understand the safety and efficacy of the drugs in order to better provide treatment options for their patients.

Fig. 1 Dextromethorphan mechanisms of action and related side effects. (Zaremba M, et al., 2023)

Our Organ Toxicity Assessment Services of Antipsychotics

Ace Therapeutics can provide comprehensive safety assessment and toxicology services to guide con-psychiatric drugs from discovery to full development support. Our highly trained staff has extensive academic, scientific, and pharmaceutical industry experience and offers a full suite of services including toxicology, toxicokinetic studies, and safety pharmacology.

• Antipsychotics Cardiotoxicity Assays

We assess and predict the cardiotoxicity of antipsychotic drugs through model simulations, in vitro screening, and animal experiments, thereby reducing the risk of cardiotoxicity.

• Antipsychotics Hepatoxicity Assays

We help clients characterize the potential hepatotoxicity of antipsychotic drugs and study the mechanisms of liver injury, from screening to IND submission.

• Antipsychotics Ocular Toxicity Assays

We can evaluate the safety and efficacy of all ocular indications caused by antipsychotic drugs, including ocular dystonia, refractive error, ocular motility disorders, corneal or lens clouding, elevated intraocular pressure, and retinitis pigmentosa.

• Antipsychotics CNS Toxicity Assays

We have developed a comprehensive testing strategy to assess neurotoxicity induced by antipsychotic drugs. We provide a methodology that will facilitate the risk assessment process for drug discovery and reduced animal use.

• Antipsychotics Hematological Toxicity Assays

We have the most trusted platform for blood toxicity screening and testing in areas ranging from early drug development to preclinical animal studies.

• Antipsychotics Carcinogenicity Assays

We can provide a variety of transgenic animal models and perform carcinogenic toxicology studies on antipsychotic drugs in accordance with GLP regulations.

• Antipsychotics Gastrointestinal Toxicity Assays

We offer a variety of in vivo and ex vivo models and analytical methods to evaluate the effects of novel antipsychotic drugs on the gastrointestinal tract and to help you understand the mechanisms of action that cause gastrointestinal toxicity.

• Antipsychotics-induced Metabolic Dysfunction Assays

We have a comprehensive metabolite and lipid analysis platform that has great potential as a companion diagnostic at several steps of the antipsychotic drug development process.

Our Full Range of Antipsychotic Drug Discovery Capabilities

• Drug discovery services
• Custom chemistry
• Computer simulation drug design (CADD)
• Discovery biology
• Animal models
• Toxicology and safety
• ADME, DMPK
• Chemistry, manufacturing, and control

Ace Therapeutics, as a preclinical R&D outsourcing service provider, is committed to providing a full range of preclinical research services to pharmaceutical companies, research institutions, and researchers worldwide to advance the process of antipsychotic drug research. If you are interested in this service, please contact us to learn how we can support you in your project.

Reference

1. Zaremba M, Serafin P, Kleczkowska P. Antipsychotic Drugs Efficacy in Dextromethorphan-Induced Psychosis. Biomedicines. 2023, 11(1):123.